- $1.32bn
- $1.43bn
- $1.36bn
- 93
- 46
- 84
- 87
2019 December 31st | C2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,326 | 1,468 | 1,619 | 1,764 | 1,359 |
Cost of Revenue | |||||
Gross Profit | 1,280 | 1,295 | 1,345 | 1,427 | 1,296 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,286 | 1,475 | 1,688 | 1,840 | 1,385 |
Operating Profit | 40.4 | -6.82 | -69 | -75.6 | -26.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 33.6 | -19.3 | -93.9 | -94.6 | -28.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 35.3 | -4.16 | -64 | -89.2 | -30 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 34.8 | -6.28 | -71.4 | -128 | -40.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 34.8 | -6.28 | -71.4 | -128 | -40.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.065 | -0.012 | -0.128 | -0.178 | -0.061 |